Diabetes in the World
Diabetes mellitus is a chronic metabolic disorder affecting 589 million adults worldwide, with Type 2 diabetes mellitus accounting for 90% of cases.
Current Solutions
Traditional treatments, such as oral hypoglycemic agents and insulin therapy, often involve frequent injections, which are associated with a high risk of complications and substantial costs.
Our Solutions
We have developed an oral product containing GLP-1 for diabetes treatment. It is designed to be more convenient and practical, making it suitable for a broad patient population.
GLP-1 as a Target Substance
GLP-1 can promote the release of insulin, and inhibits the release of glucagon. It also activates a part of the brain to produce a sense of satiety.
E-coli as an Expression Host
The modified plasmid was introduced into E-coli, and the bacteria were able to produce GLP-1 in the intestinal tract.
Jelly as Edible Format
Calcium-alginate beads encapsulate E-coli in a protective gel and are embedded in jelly to create a delicious, portable "VitaPop Jelly".
Our Futrue
